(29 days)
Not Found
No
The device description details a pneumatically controlled system with electronically controlled pump and solenoid valves. The software controls pressure and cycle times based on pre-set parameters, not adaptive learning or pattern recognition. There is no mention of AI/ML in the device description, intended use, or performance studies.
Yes
The intended use explicitly states its purpose is to "help prevent the onset of DVT in patients, by stimulating blood flow in the legs," and to "aid in the treatment and healing of stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency, and reduction of edema in the lower limbs," which are all therapeutic claims.
No
The device is described as a system that aids in the prevention and treatment of various conditions by stimulating blood flow, rather than diagnosing them. It does not perform any diagnostic functions or analyze patient data to identify diseases or conditions.
No
The device description clearly outlines hardware components including a pump unit, solenoid valves, leg cuff(s), pressure transducer, and a rechargeable battery. While it mentions integrated system software, the device's primary function relies on the interaction of these physical components.
Based on the provided information, the DVTcare™ CA5 is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states that the device is used to prevent DVT by stimulating blood flow in the legs and as an aid in the prophylaxis for DVT. It also mentions aiding in the treatment and healing of various conditions. These are all therapeutic or preventative actions performed on the patient's body.
- Device Description: The device description details a system that uses pneumatic compression (air pressure) applied to the legs via cuffs. This is a physical intervention applied externally to the body.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
IVD devices are specifically designed to perform tests on samples taken from the body to provide diagnostic information. The DVTcare™ CA5 operates by applying physical pressure to the body.
N/A
Intended Use / Indications for Use
The DVTcare™ CA5 is intended to be an easy to use, portable system that is prescribed by healthcare professionals, to help prevent the onset of DVT in patients, by stimulating blood flow in the legs (simulating muscle contractions). Furthermore, the unit can be used as an aid in the prophylaxis for DVT by persons traveling, or those expecting to be stationary for long periods of time (> 4 hours). This device can also be used to: aid in the prevention of DVT, enhance blood circulation, diminish post-operative pain and swelling, reduce wound healing time, and aid in the treatment and healing of stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency, and reduction of edema in the lower limbs.
Product codes (comma separated list FDA assigned to the subject device)
JOW
Device Description
The DVTcare™ CA5 system is a light weight, portable, prescriptive device that helps stimulate blood flow in the legs through the use of pneumatically controlled, single chamber leg cuff(s), actuated by an electronically controlled pump unit and solenoid valves. All pump control unit components are protectively housed in a plastic shell except the outer membrane switch (needed for user interface), 2 plastic quick disconnects for air tube connection, and an external power supply input jack. The option exists for the unit to be used in single leg or double leg modes.
During operation, the pump unit provides air to one cuff through flexible plastic tubing, inflating it to a specified pressure, to compress the lower limb, thus aiding venous return. Air pressure and delivery are monitored by a pressure transducer and integrated system software contained in the plastic control unit. Immediately after the pressure transducer detects that the cuff has achieved the current set pressure, the cuff deflates to ambient pressure. This allows the blood flow to return to the limb. To provide maximum flexibility, the CA5 also provides adjustable cycle times. System software prevents users from entering a cycle time, for any one limb, to be less than 60 seconds. This is done to prevent excessive stimulation of the limb.
In single leg mode, this cycle repeats until the unit is turned off. In double leg mode the first and second leg cuffs do not fill simultaneously. The second leg begins its fill once the first leg has reached the midpoint of the overall cycle time for both legs. In double leg mode, air flow is directed to fill the second bladder cuff using the same cycle profile as the initial leg. After completing the fill, exhaust and rest period of leg 1, the control unit directs air flow to the second leg and fills that bladder cuff until the set pressure is reached and exhausted. The cycle repeats, reverting air flow to the initial leg.
The control unit is supplied with a non-serviceable, rechargeable battery, to allow user portability, and a power supply transformer for mains connection.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
legs, lower limb(s)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
prescribed by healthcare professionals
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical validation including electrical safety, EMC, mechanical integrity, environmental and life cycle testing have shown that the DVTcare™ CA5 has performance characteristics substantially equivalent to or superseding the listed predicate devices. The CA5 has been validated by DVTCare at a design validation level based on the requirements of UL 60601-1, CSA C22.2 NO 601.1 and CENELEC EN 60601-1 and confirmed by an accredited test lab. Being portable, CA5 samples were also tested to MIL-STD 810D, section 514.3-1 for vibrational integrity. Additional bench testing has verified equivalent pressure delivery, cuff (garment) fill time, cycle time and system operation as the predicate devices listed.
No clinical testing was performed on the DVTCare CA5, however test results of the predicate devices have been compared in the following published clinical studies : Evaluation of Intermittent Pneumatic Compression Devices (Orthopedics 24(3):257-261, 2001), and Venous hemodynamics after total knee arthroplasty: Evaluation of active dorsal to plantar flexion and several mechanical compression devices (Journal of Bone and Joint Surgery, Nov 1998). Test subjects for the former study consisted of five healthy individuals aged 21-35 years old and the later consisted of ten patients who were about to have a primary unilateral knee arthroplasty for osteoarthritis. This patient group's mean age was 68 years old with mean weight of 85kg. In summary, the conclusions of each study state that the use of intermittent pneumatic compression devices is useful in decreasing the risk of postoperative DVT. The Venodyne model produced a mean blood flow velocity of 76.2 +/-23.77 using an average pressure of 43mmHg, a compression time of 11.6 seconds and a total cycle time of 60 seconds. These values are extremely similar to corresponding default parameters used by the DVTCare CA5. Since the methods of pressure delivery and operation are identical in both systems, significant equivalence is concluded.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K023573, K022340, K011318, K961166
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.5800 Compressible limb sleeve.
(a)
Identification. A compressible limb sleeve is a device that is used to prevent pooling of blood in a limb by inflating periodically a sleeve around the limb.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo for "DVTCare, LLC". To the left of the company name is a graphic of a grid with four black dots. Below the company name is the address "731 Construction Ct., Suite B, Zeeland, MI 49464".
731 Construction Ct. Suite
510(k) Summary DVTcare™ CA5
510(k) Number K 061125
MAY 2 3 2006
Summary Prepared: Date 12/19/05
Submitter:
Doctor's Orders, Inc. 731 Construction Court, Suite B Zeeland, MI 49464 Phone: 616-931-9939 Fax: 616- 582-6200
Contact Person:
Jerry Kulas Development Engineer
3rd Party Reviewer
Intertek - ETL SEMKO 1365 Adams Court Menlo Park, CA 94025 (650) 463-2946
Name of the Device:
Trade Name: DVTcare™ CA5 Model #: CA5 Common or usual name: Compressible Limb Sleeve Device Classification Name: Compressible Limb Sleeve Class II Product Code: JOW Regulation No. CFR Part 870.5800 Establishment Registration Number: 3004739895
1
Image /page/1/Picture/0 description: The image shows the logo for "DVTCare, LLC". The logo includes a grid-like design with four black circles on the left side. Below the logo is the address "731 Construction Ct. Suite B Zeeland, MI 49464".
Statement of Substantial Equivalence:
The DVTcare™ CA5 is substantially equivalent to the following commercially available devices:
WizAir DVT (510k number: K023573) in that the basis of operation of both devices uses intermittent, pneumatic compression to simulate muscle contractions in the legs aiding the return of venous flow. Compression is achieved by air delivery, through flexible plastic tubing, to inflatable bladders, that are wrapped around the limb(s), to transmit the pneumatic force to the leg. The air delivery is controlled by a microprocessor controlled pump and valve system. Both devices are light weight, portable and can operate on rechargeable batteries alone or while being connected to 110 VAC mains. Indications for use are similar. Cycle operating parameters are similar in pressure delivery and cycle time.
TravelAir Portable Compression System (510k number: K022340) in that the basis of operation of both devices uses intermittent, pneumatic compression to simulate muscle contractions in the legs aiding the return of venous flow. Compression is achieved by air delivery, through flexible plastic tubing, that are terminated with CPC quick lock connectors, to inflatable bladders, that are wrapped around the limb(s), to transmit the pneumatic force to the leg. Bladders are composed of PVC. The air delivery is controlled by a microprocessor controlled pump and valve system. Both devices are light weight, portable and can operate on rechargeable batteries alone or while being connected to 110 VAC mains. Indications for use are similar. Cycle operating parameters are similar in pressure delivery and cycle time.
Venodyne Advantage Plus (510k number: K011318) in that the basis of operation of both devices uses intermittent, pneumatic compression to simulate muscle contractions in the legs aiding the return of venous flow. Compression is achieved by air delivery, through flexible plastic tubing, to single chamber inflatable bladders, that are wrapped around the lower limb(s), to transmit the pneumatic force to the leg. The air delivery is controlled by a microprocessor controlled pump and valve system that are encased in a molded plastic enclosure. Indications for use are similar. Cycle operating parameters are similar in pressure delivery and cycle time.
2
Image /page/2/Picture/0 description: The image shows the logo for "DVTCare, LLC". The logo includes a grid-like design with three black circles on the left side. Below the logo is the address "731 Construction Ct. Suite B Zeeland, MI 49464".
Flowtron Excel AC550 (510k number: K961166) is similar in operation and intended use to the DVTCare CA5. Both incorporate adjustable pressures (between 20mmHg and 65mmHg), single and double leg modes, audible and visual alarms for system monitoring and fault recognition, soft Nylon covered, single chambered garments (cuffs) that wrap around the calf and held in place with hook and loop fasteners.
Device Description:
The DVTcare™ CA5 system is a light weight, portable, prescriptive device that helps stimulate blood flow in the legs through the use of pneumatically controlled, single chamber leg cuff(s), actuated by an electronically controlled pump unit and solenoid valves. All pump control unit components are protectively housed in a plastic shell except the outer membrane switch (needed for user interface), 2 plastic quick disconnects for air tube connection, and an external power supply input jack. The option exists for the unit to be used in single leg or double leg modes.
During operation, the pump unit provides air to one cuff through flexible plastic tubing, inflating it to a specified pressure, to compress the lower limb, thus aiding venous return. Air pressure and delivery are monitored by a pressure transducer and integrated system software contained in the plastic control unit. Immediately after the pressure transducer detects that the cuff has achieved the current set pressure, the cuff deflates to ambient pressure. This allows the blood flow to return to the limb. To provide maximum flexibility, the CA5 also provides adjustable cycle times. System software prevents users from entering a cycle time, for any one limb, to be less than 60 seconds. This is done to prevent excessive stimulation of the limb.
In single leg mode, this cycle repeats until the unit is turned off. In double leg mode the first and second leg cuffs do not fill simultaneously. The second leg begins its fill once the first leg has reached the midpoint of the overall cycle time for both legs. In double leg mode, air flow is directed to fill the second bladder cuff using the same cycle profile as the initial leg. After completing the fill, exhaust and rest period of leg 1, the control unit directs air flow to the second leg and fills that bladder cuff until the set pressure is reached and exhausted. The cycle repeats, reverting air flow to the initial leg.
The control unit is supplied with a non-serviceable, rechargeable battery, to allow user portability, and a power supply transformer for mains connection.
3
Image /page/3/Picture/0 description: The image shows the logo for "DVTCare, LLC" along with their address. The logo is black and white and features a stylized design to the left of the company name. The address is "731 Construction Ct., Suite B, Zeeland, MI 49464".
Construction Ct.
Intended Use:
The DVTcare™ CA5 is intended to be an easy to use, portable system that is prescribed by healthcare professionals, to help prevent the onset of DVT in patients, by stimulating blood flow in the legs (simulating muscle contractions). Furthermore, the unit can be used as an aid in the prophylaxis for DVT by persons traveling, or those expecting to be stationary for long periods of time (> 4 hours). This device can also be used to: aid in the prevention of DVT, enhance blood circulation, diminish post-operative pain and swelling, reduce wound healing time, and aid in the treatment and healing of: stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency, and reduction of edema in the lower limbs.
Contraindications:
The DVTcare™ CA5 should not be used to treat the following conditions:
- Persons with suspected, active or untreated: deep vein thrombosis, . ischemic vascular disease, severe arteriosclerosis, pulmonary edema, congestive heart failure, thrombophlebitis or an active infection.
- · It is not recommended for use on a leg where the cuffs would interfere-with the following conditions: vein ligation, gangrene, dermatitis, open wounds, a recent skin graft, massive edema or extreme deformity of the leg.
- · Not for use with patients with neuroapathy.
- Do not use on extremities that are insensitive to pain. .
- Do not use where increased venous or lymphatic return is undesirable. .
- · Leg cuffs are not to be used in direct contact with skin.
4
Image /page/4/Picture/0 description: The image shows the logo for "DVTCare, LLC". The logo has a grid-like design with four black circles on the left side. Below the logo is the address "731 Construction Ct. Suite B Zeeland, MI 49464".
Technological Characteristics:
The DVTcare™ CA5 is similar to the predicate devices listed above in function and operating principles to achieve identical results however, the CA5 possesses a combination of features that each of the four predicate devices incorporate individually. The CA5 combines these features to offer greater treatment flexibility due to portability, adjustable pressure, and cycle time capabilities. All systems use microprocessor controlled pumps to deliver pressurized air (approximately 40mmHg) to bladders that are attached to the patient's lower limbs, using a cycle of approximately 60 seconds / leg as prescribed by a healthcare provider. Each cycle consists of one inflation (fill time approximately 10-12 seconds) followed by deflation. The CA5 has the capability of allowing a healthcare professional the following feature adjustment options: pressure set point (20-65 mmHg), hold time (0 seconds, not adjustable), cycle time (60-75 seconds). The cycle time is the length of time for one complete cycle on one leg including fill time, exhaust, and idle time (relaxation).
Patient access to these pressure and cycle time adjustments is prevented by requiring the healthcare provider to enter an access code for modification. The unit's default settings are similar to predicate devices in fill time (approximately 10 seconds), pressure (40mmHg), and cycle time (approximately 60 seconds) as noted above.
The CA5 uses similar means for pressure delivery as the predicate devices. Pressurized air is delivered by the pump to the leg cuffs via flexible, plastic air tubes connected to the plastic pump / control unit by locking, quick disconnect couplings. Like the Flowtron Excel, the CA5 leg cuffs are comprised of single bladder PVC chambers encased in a soft Nylon material to increase patient comfort and compliance.
Like the WizAir DVT and TravelAir the microprocessor and pump units are powered by internal battery supplies and can be connected to the mains power supply for operation and recharging.
5
Image /page/5/Picture/0 description: The image shows the logo for "DVTcare, LLC". The logo consists of a grid of lines and circles on the left, followed by the text "DVTcare, LLC" in a bold, sans-serif font. Below the logo is the address "731 Construction Ct. Suite B Zeeland, MI 49464".
731 Construction Ct. Suite B Zeeland, MI 494
Non-Clinical Testing
Nonclinical validation including electrical safety, EMC, mechanical integrity, environmental and life cycle testing have shown that the DVTcare™ CA5 has performance characteristics substantially equivalent to or superseding the listed predicate devices. The CA5 has been validated by DVTCare at a design validation level based on the requirements of UL 60601-1, CSA C22.2 NO 601.1 and CENELEC EN 60601-1 and confirmed by an accredited test lab. Being portable, CA5 samples were also tested to MIL-STD 810D, section 514.3-1 for vibrational integrity. Additional bench testing has verified equivalent pressure delivery, cuff (garment) fill time, cycle time and system operation as the predicate devices listed.
Clinical Testing
No clinical testing was performed on the DVTCare CA5, however test results of the predicate devices have been compared in the following published clinical studies : Evaluation of Intermittent Pneumatic Compression Devices (Orthopedics 24(3):257-261, 2001), and Venous hemodynamics after total knee arthroplasty: Evaluation of active dorsal to plantar flexion and several mechanical compression devices (Journal of Bone and Joint Surgery, Nov 1998) . Test subjects for the former study consisted of five healthy individuals aged 21-35 years old and the later consisted of ten patients who were about to have a primary unilateral knee arthroplasty for osteoarthritis. This patient group's mean age was 68 years old with mean weight of 85kg. In summary, the conclusions of each study state that the use of intermittent pneumatic compression devices is useful in decreasing the risk of postoperative DVT. The Venodyne model produced a mean blood flow velocity of 76.2 +/-23.77 using an average pressure of 43mmHg, a compression time of 11.6 seconds and a total cycle time of 60 seconds. These values are extremely similar to corresponding default parameters used by the DVTCare CA5. Since the methods of pressure delivery and operation are identical in both systems, significant equivalence is concluded.
Summary Conclusion:
Per the requirements of 21CFR807, surrogate clinical data, non-clinical validation testing and the information provided in the accompanying 510k pre-market submission, Doctor's Orders cocludes that the DVTcare™ CA5 is safe, effective and performs in a manner that is substantially equivalent to the predicate devices listed above.
6
Image /page/6/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes forming its body and wings. The eagle is enclosed within a circle, with the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES. USA" surrounding the upper half of the circle. The logo is black and white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAY 2 3 2006
Doctor's Orders, Inc. c/o Mr. Daniel W. Lehtonen Intertek Testing Services 2307 East Aurora Road Twinsburg, Ohio 44087
Re: K061125
DVTcare™ CA5 Regulation Number: 21 CFR 870.5800 Regulation Name: Compressible Limb Sleeve Regulatory Class: Class II (two) Product Code: JOW Dated: April 21, 2006 Received: April 24, 2006
Dear Mr. Lehtonen:
We have reviewed your Section 510(k) premarket notification of intent to market the device w for a reveal above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for asso surved in the enactment date of the enactment date of the Medical Device Amendments, or to conimer of the 112) 2011-03-120, in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
7
Page 2 - Mr. Daniel W. Lehtonen
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Duna R. Wehner
Image /page/7/Picture/5 description: The image shows a black and white drawing of a signature. The signature appears to be stylized and illegible. The lines are thick and bold, and the signature is compact.
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
8
Indications for Use
510(k) Number (if known):
Device Name: DVTCare CA5
Indications for Use: The DVTcare™ CA5 is intended to be an easy to use, portable system that is prescribed by healthcare professionals, to help prevent the onset of DVT in patients, by stimulating blood flow in the legs (simulating muscle contractions). Furthermore, the unit can be used as an aid in the prophylaxis for DVT by persons traveling, or those expecting to be stationary for long periods of time (> 4 hours). This device can also be used to: aid in the prevention of DVT, enhance blood circulation, diminish post-operative pain and swelling, reduce wound healing time, and aid in the treatment and healing of stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency, and reduction of edema in the lower limbs.
Prescription Use ﺮﺍ (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
DMR R.V. Jones
(Division Sign-Off) Division of Cardiovascular Devices
Page 1 of 1
510(k) Number_k 66 1125